Washington – Senate Finance Committee Chairman Chuck Grassley
(R-Iowa) today released the following statement regarding President Donald
Trump’s executive
order encouraging domestic manufacturing of drugs and other medical goods
critical to public health.
“The
coronavirus pandemic exposed many weaknesses in our medical supply chain.
There’s no question that our reliance on certain countries for personal
protective equipment, medicine and other goods make containing this deadly
disease much tougher. It’s now clear that supply chain diversification and
increased domestic manufacturing of medical products is critical to preserving
our country’s ability to respond to major public health crises,” Grassley
said. “Unfortunately, the coronavirus pandemic caused health care workers,
patients, businesses and all Americans to learn this the hard way. This
shouldn’t be a mistake we make twice. These are structural problems exacerbated
by years of inaction from previous administrations of both parties. President
Trump is right to do all he can to encourage domestic manufacturing. It will be
up to Congress to finish the job.”
Grassley
has long been an advocate for increased access to affordable prescription drugs
and this year authored
the bipartisan Prescription Drug Pricing Reduction Act of 2020.
Last
week, Grassley led a two-part oversight hearing on protecting the reliability
of the U.S. medical supply chain during the COVID-19 pandemic. Those hearings
can be viewed here
and here
and Grassley’s statements can be found here
and here.
In
June, Grassley led a hearing
on the Food and Drug Administration’s (FDA) foreign drug manufacturing
inspection process. His statement from that hearing can be found here.